We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,615

FAQ on notice of coverage options for ACA’s new health insurance marketplace
  • McDermott Will & Emery
  • USA
  • September 12 2013

In a brief Frequently Asked Question (FAQ) document quietly issued yesterday, the U.S. Department of Labor formally clarified there is no penalty


Claim Construction Disputes Should Be Affirmatively and Formally Raised
  • McDermott Will & Emery
  • USA
  • October 26 2016

Addressing the preservation of claim construction disputes for appeal and issues of divided infringement, the US Court of Appeals for the Federal


ONC issues revised certification criteria for EHR technology used to earn incentive payments
  • McDermott Will & Emery
  • USA
  • September 18 2012

The Office of the National Coordinator for Health Information Technology coordinated its September 4, 2012, release of the 2014 Edition Electronic Health Record (EHR) Certification Criteria with the Centers for Medicare & Medicaid Services’ release on the same day of updated meaningful use (MU) criteria for eligible providers to demonstrate MU and earn EHR incentive payments under Stage 2 of the Medicare and Medicaid EHR Incentive Programs


Federal court vacates 340B rule regarding orphan drugs
  • McDermott Will & Emery
  • USA
  • June 2 2014

On May 23, 2014, the U.S. District Court for the District of Columbia issued a Memorandum Opinion in Pharmaceutical Research and Manufacturers of


“Commercially reasonable efforts” diligence obligations in life science M&A
  • McDermott Will & Emery
  • USA
  • May 29 2014

More than 80 percent of all deals in the pharmaceutical, medical device and biotech industries include an earnout structure that provides some type


Gilead warns: examine patent portfolios for double patenting pitfalls
  • McDermott Will & Emery
  • USA
  • May 29 2014

Addressing invalidation of a patent for obviousness-type double patenting, the U.S. Court of Appeals for the Federal Circuit vacated and remanded a


U.S. Supreme Court hears oral argument in Phoebe Putney hospital merger challenge
  • McDermott Will & Emery
  • USA
  • November 27 2012

In oral argument in FTC v Phoebe Putney Health System, Supreme Court Justices focused on whether the state legislature clearly articulated a state policy to displace competition with regulation, in a case challenging the application of the state action doctrine to a hospital merger to monopoly


Sixth Circuit Revives Home Health Qui Tam Based on Pre-Escobar Standards; Dissent Criticizes Majority for Engaging in Rulemaking
  • McDermott Will & Emery
  • USA
  • October 6 2016

On September 30, the US Court of Appeals for the Sixth Circuit reversed dismissal of a relator’s False Claims Act (FCA) claims against providers of


ACA proposed rule to require health insurers to certify compliance with HIPAA electronic transaction requirements
  • McDermott Will & Emery
  • USA
  • January 9 2014

The U.S. Department of Health and Human Services issued a proposed rule to implement the ACA requirement that health insurers and other HIPAA-covered


Detroit nurses object to Sixth Circuit reviewing class certification decision
  • McDermott Will & Emery
  • USA
  • October 15 2013

On October 11, 2013, the plaintiffs in the Detroit nurses litigation who have accused Detroit-area hospitals of conspiring to suppress their wages